PMVP

PMV Pharmaceuticals, Inc.

Catalyst AI-extracted

rezatapopt

platinum-resistant/refractory ovarian cancer

Countdown

178days

Catalyst readout · ~ Jan 1, 2027 estimated

What's at stake A key catalyst for rezatapopt (platinum-resistant/refractory ovarian cancer) is expected ~ Jan 1, 2027.

Primary source · SEC 8-K verified 14h ago

“PMV Pharma anticipates submitting a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027.”

Add to calendar Post on X Reddit

Provenance